Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Epidemiology and surveillance of Gram-negative infections caused by carbapenemase-producing organisms (CPOs) in the UK
    Release Date:
    Review Process: Expert Review Panel
    Research Internal Medicine United Kingdom
    Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC)
    Release Date:
    Partner: ALK Positive
    Review Process: Pfizer Internal
    Education Oncology All
    Quality Improvement Solutions for the Diagnosis and Management of Migraine and Headache Disorders
    Release Date:
    Partner: American Headache Society
    Review Process: Expert Review Panel
    Quality Improvement Internal Medicine Canada, USA
    Shared Decision Making in Hemophilia Patient Care
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease China
    Real-World Atopic Dermatitis: Italian Insights Grant
    Release Date:
    Review Process: Expert Review Panel
    Research Inflammation & Immunology Italy
    Evolving Treatment Options in First-Line Metastatic Urothelial Carcinoma (mUC) and Muscle Invasive Bladder Cancer (MIBC)
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology All
    Optimizing Care for patients with Muscle Invasive Bladder Cancer (MIBC)
    Release Date:
    Review Process: Expert Review Panel
    Translation: French (link)
    Quality Improvement Oncology Canada
    Optimizing HRRm Testing and Workflow Integration in mCSPC
    Release Date:
    Review Process: Expert Review Panel
    Translation: French (link)
    Quality Improvement, Research Oncology Canada
    Driving Timely Biomarker Testing to Optimize Treatment Decisions for Colorectal Cancer Patients Across Canada
    Release Date:
    Partner: Colorectal Cancer Canada (CCC)
    Review Process: Expert Review Panel
    Translation: French (link)
    Quality Improvement, Research Oncology Canada
    Antimicrobial Stewardship —Treatment optimization under antibiotics appropriate use policy in China
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Collaborative Community Oncology Support for Therapy Management in Relapsed/Refractory Multiple Myeloma (RRMM)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Italy, Japan, Spain, United Kingdom
    Emerging Data and Unmet Needs in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology All
    Education in the Era of Emerging Hemophilia Therapy (Round 2)
    Release Date:
    Review Process: Expert Review Panel
    Education Rare Disease USA
    Improving Actionable Biomarker Testing Through Technology-Enabled Solutions
    Release Date:
    Partner: Conquer Cancer, The ASCO Foundation
    Review Process: Expert Review Panel
    Quality Improvement Oncology USA
    USP <797> Pharmaceutical Compounding-Sterile Preparations: Challenges and Special Considerations
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA
    Improving Shared Decision Making in Hemophilia: Visiting Professorship Program
    Release Date:
    Partner: Hemostasis & Thrombosis Research Society (HTRS)
    Review Process: Expert Review Panel
    Education Rare Disease USA
    Pharmacokinetics-Pharmacodynamics (PK-PD) Profile, Effectiveness and Safety of ATM-AVI in Special Populations
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Unmet Need and Emerging Data in Muscle Invasive Bladder Cancer (MIBC)
    Release Date:
    Partner: Astellas
    Review Process: Pfizer Internal
    Education Oncology USA
    Bridging the Inflammatory Dermatosis Care Divide with Teledermatology
    Release Date:
    Partner: The George Washington University
    Review Process: Expert Review Panel
    Quality Improvement Inflammation & Immunology USA
    Impact of Rapid Diagnostic Tests (RDTs) on Treatment Pattern and Outcomes in Patients with Carbapenem-Resistant (CR) Pathogens
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology China
    Global Request for Proposals – Pfizer Clostridioides difficile (C. difficile) Research Collaboration
    Release Date:
    Review Process: Pfizer Internal
    Call for Collaborator(s) Vaccines France, Germany